Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
87.40
+0.90 (1.04%)
At close: Feb 20, 2026, 4:00 PM EST
88.88
+1.48 (1.69%)
After-hours: Feb 20, 2026, 5:24 PM EST

Kymera Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-295.12-223.86-146.96-154.81-100.22-45.59
Depreciation & Amortization
8.277.373.572.982.41.76
Loss (Gain) From Sale of Assets
----0.02-
Asset Writedown & Restructuring Costs
-----0.33
Loss (Gain) From Sale of Investments
-10.1-13.98-5.230.895.811.57
Stock-Based Compensation
59.2555.0143.1235.4824.975.19
Other Operating Activities
3.864.93----
Change in Accounts Receivable
1.3217.82-16.23-2.41.3-1.43
Change in Accounts Payable
-0.99-0.312.040.250.050.99
Change in Unearned Revenue
17.21-41.08-8.61-37.77-69.36117.4
Change in Other Net Operating Assets
-11.62-0.425.482.36.087.91
Operating Cash Flow
-227.93-194.5-102.83-153.09-128.9588.13
Operating Cash Flow Growth
-----392.21%
Capital Expenditures
-2.28-12.84-34.48-2.84-1.6-9.1
Investment in Securities
-55.82-391.24174.3723.36-98.24-413.49
Investing Cash Flow
-58.1-404.08139.8920.52-99.84-422.59
Long-Term Debt Repaid
--1.58-0.08-1.13-0.85-0.55
Net Debt Issued (Repaid)
-1.37-1.58-0.08-1.13-0.85-0.55
Issuance of Common Stock
317.99638.794.27154.3251.53196.84
Other Financing Activities
-28.36-28.36--0.17-0.4-
Financing Cash Flow
288.26608.854.19153250.28289.26
Net Cash Flow
2.2410.2741.2520.4321.5-45.2
Free Cash Flow
-230.21-207.34-137.31-155.92-130.5479.03
Free Cash Flow Growth
-----354.92%
Free Cash Flow Margin
-526.37%-440.47%-174.71%-332.98%-179.24%232.22%
Free Cash Flow Per Share
-2.81-2.76-2.35-2.89-2.724.55
Cash Interest Paid
0.30.210.160.180.160.12
Levered Free Cash Flow
-139.94-126.83-97.62-90.21-58.339.76
Unlevered Free Cash Flow
-139.73-126.68-97.49-90.1-58.1939.83
Change in Working Capital
5.92-23.972.68-37.62-61.92124.87
Updated Nov 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q